Thomas Catinazzo Sells 1,695 Shares of Relay Therapeutics (NASDAQ:RLAY) Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo sold 1,695 shares of the business’s stock in a transaction on Wednesday, January 28th. The stock was sold at an average price of $8.45, for a total value of $14,322.75. Following the transaction, the chief financial officer directly owned 249,301 shares of the company’s stock, valued at $2,106,593.45. This trade represents a 0.68% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Thomas Catinazzo also recently made the following trade(s):

• On Tuesday, January 27th, Thomas Catinazzo sold 13,820 shares of Relay Therapeutics stock. The shares were sold at an average price of $7.62, for a total transaction of $105,308.40.

Relay Therapeutics Price Performance

RLAY stock opened at $7.66 on Friday. The stock has a market cap of $1.33 billion, a price-to-earnings ratio of -4.38 and a beta of 1.55. The company has a 50 day simple moving average of $7.97 and a 200 day simple moving average of $5.97. Relay Therapeutics, Inc. has a 1 year low of $1.77 and a 1 year high of $9.04.

Relay Therapeutics (NASDAQ:RLAY) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.04). On average, equities research analysts anticipate that Relay Therapeutics, Inc. will post -2.55 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently issued reports on RLAY. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Relay Therapeutics in a research note on Friday, January 9th. Wells Fargo & Company upgraded shares of Relay Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $6.00 to $13.00 in a report on Friday, December 12th. Finally, Oppenheimer raised shares of Relay Therapeutics from a “market perform” rating to an “outperform” rating and set a $14.00 price objective on the stock in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $16.57.

Hedge Funds Weigh In On Relay Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Relay Therapeutics by 26.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,422 shares of the company’s stock valued at $71,000 after buying an additional 1,757 shares during the period. Cresset Asset Management LLC boosted its position in shares of Relay Therapeutics by 5.0% during the 3rd quarter. Cresset Asset Management LLC now owns 38,932 shares of the company’s stock valued at $203,000 after purchasing an additional 1,848 shares in the last quarter. Vanguard Personalized Indexing Management LLC grew its stake in Relay Therapeutics by 8.1% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 27,871 shares of the company’s stock worth $145,000 after purchasing an additional 2,079 shares during the period. Prelude Capital Management LLC increased its holdings in Relay Therapeutics by 18.7% in the third quarter. Prelude Capital Management LLC now owns 19,700 shares of the company’s stock worth $103,000 after purchasing an additional 3,100 shares in the last quarter. Finally, Los Angeles Capital Management LLC lifted its stake in Relay Therapeutics by 5.0% in the second quarter. Los Angeles Capital Management LLC now owns 68,615 shares of the company’s stock valued at $237,000 after buying an additional 3,275 shares during the period. Institutional investors own 96.98% of the company’s stock.

Key Stories Impacting Relay Therapeutics

Here are the key news stories impacting Relay Therapeutics this week:

• Positive Sentiment: Technical/quote signal — MarketBeat notes an intraday uptick and that shares are trading above the 200‑day moving average, a constructive technical sign that can attract momentum buyers. MarketBeat RLAY quote
• Positive Sentiment: Analyst support — Recent upgrades (Oppenheimer to Outperform; Wells Fargo to Overweight) and a consensus “Moderate Buy” rating give fundamental/flow support that can limit downside from short‑term selling. Analyst commentary
• Neutral Sentiment: Insiders still hold large stakes — filings show executives retain hundreds of thousands of shares after the sales, so these transactions reduce ownership modestly but are not a change of control signal. (See SEC filings for details.) SEC ownership filing
• Negative Sentiment: CFO selling — CFO Thomas Catinazzo sold 13,820 shares on Jan. 27 (~$105k at ~$7.62) and an additional 1,695 shares on Jan. 28 (~$14.3k at ~$8.45). Multi‑day sales by the CFO amplify concerns and can sap near‑term sentiment. Catinazzo filings
• Negative Sentiment: Other insider sales clustered over Jan. 27–28 — Director/executive Peter Rahmer sold ~11.7k and 1,354 shares across two days; Donald Bergstrom sold ~18.9k and 2,686 shares. The concentration and timing of sales by multiple insiders increase short‑term selling pressure. Rahmer filings Bergstrom filings
• Negative Sentiment: Market commentary citing a notable intraday decline (~5.2%) amplifies negative sentiment and may trigger momentum selling even if fundamentals are unchanged. Why RLAY is down 5.18%

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.